SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-24-005118
Filing Date
2024-07-30
Accepted
2024-07-30 07:00:51
Documents
17
Period of Report
2024-07-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 37265
2 EXCLUSIVE LICENSE AGREEMENT cns_ex1001.htm EX-10.1 293396
3 STOCK PURCHASE AGREEMENT cns_ex1002.htm EX-10.2 156278
4 PRESS RELEASE cns_ex9901.htm EX-99.1 24365
8 GRAPHIC image_001.jpg GRAPHIC 8211
  Complete submission text file 0001683168-24-005118.txt   798040

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cnsp-20240729.xsd EX-101.SCH 3018
6 XBRL LABEL FILE cnsp-20240729_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE cnsp-20240729_pre.xml EX-101.PRE 22361
19 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3802
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 241154348
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)